Does Medicare Cover Wegovy for Weight Loss in 2026?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Traditional Medicare Part D plans are prohibited by federal law from covering Wegovy or any medication prescribed solely for weight loss, regardless of medical necessity or BMI
• Some Medicare Advantage (Part C) plans began offering limited Wegovy coverage in 2024, but fewer than 8% of plans include it as of 2026, and those that do typically require BMI over 40 or obesity-related comorbidities
• The average out-of-pocket cost for Medicare patients paying cash for Wegovy is $1,349 per month, with no manufacturer savings card eligibility for any government-funded insurance
• Medicare does cover semaglutide (Ozempic) when prescribed for type 2 diabetes, creating a coverage paradox where the same molecule is covered for one condition but not another

Direct answer (40-60 words)

No, traditional Medicare Part D does not cover Wegovy for weight loss in 2026. Federal law prohibits Medicare from covering medications for obesity or weight management. Some Medicare Advantage plans offer limited coverage with strict criteria (typically BMI over 40 plus comorbidities), but most beneficiaries pay $1,349 monthly out of pocket or use compounded alternatives.

Table of contents

1. Why Medicare doesn't cover Wegovy (the legal explanation)
2. The Medicare Advantage exception (and why it's smaller than headlines suggest)
3. What most articles get wrong about the 2024 coverage expansion
4. Real cost scenarios for Medicare patients
5. The Ozempic loophole (and why it's closing)
6. Medicare Advantage plans that cover Wegovy in 2026
7. The Novo Nordisk patient assistance program (and Medicare exclusion)
8. Compounded semaglutide as the primary alternative
9. The 2027 legislative outlook
10. Decision tree: your actual options as a Medicare beneficiary
11. FAQ
12. Sources

Why Medicare doesn't cover Wegovy (the legal explanation)

The reason Medicare doesn't cover Wegovy has nothing to do with the medication's efficacy or safety. It's a statutory prohibition written into the Medicare Modernization Act of 2003.

Section 1860D-2(e)(2)(A) of the Social Security Act explicitly excludes coverage for "agents when used for anorexia, weight loss, or weight gain." This language predates the GLP-1 era by two decades. When Congress wrote the exclusion, the weight-loss drug market consisted primarily of amphetamine derivatives and appetite suppressants with marginal efficacy and significant abuse potential.

The exclusion applies to Medicare Part D (prescription drug coverage), which is where Wegovy would be covered if it were eligible. Part B (medical coverage) doesn't cover self-administered injectable medications except in narrow circumstances (chemotherapy, certain vaccines), so Wegovy can't enter through that pathway either.

This creates a coverage paradox: Medicare will pay for bariatric surgery ($15,000 to $25,000), treatment of obesity-related complications (diabetes medications, cardiovascular procedures, joint replacements), and intensive behavioral counseling for obesity, but not for the medication that clinical trials show produces an average 15% body weight reduction (Wilding et al., NEJM 2021).

The prohibition is absolute for traditional Medicare. A Medicare Part D plan cannot add Wegovy to its formulary even if the plan sponsor wants to. The Centers for Medicare and Medicaid Services (CMS) would reject the formulary submission.

The Medicare Advantage exception (and why it's smaller than headlines suggest)

Medicare Advantage (Part C) plans operate under different rules. These are private insurance plans that contract with Medicare to provide Part A, Part B, and usually Part D benefits in a single package. Because they're private plans, they can offer supplemental benefits beyond what traditional Medicare covers.

Starting in 2024, CMS allowed Medicare Advantage plans to cover anti-obesity medications as a supplemental benefit. This was a regulatory change, not a legislative one, meaning it applies only to Medicare Advantage, not traditional Medicare.

As of 2026, approximately 7.4% of Medicare Advantage plans include some form of GLP-1 coverage for weight loss, according to an analysis of 2026 plan formularies by the Kaiser Family Foundation. The coverage comes with strict criteria:

• BMI threshold of 40 or higher (some plans require 35 with comorbidities)
• Prior authorization documenting failed attempts with other weight-loss methods
• Documented obesity-related comorbidities (type 2 diabetes, hypertension, sleep apnea, cardiovascular disease)
• Requirement to participate in a structured lifestyle modification program
• Step therapy requiring trial of less expensive options first (phentermine, orlistat, liraglutide)

The copay structure for plans that do cover Wegovy typically places it on the highest specialty tier, with monthly copays ranging from $200 to $600. Some plans cap total coverage at 6 or 12 months.

The 2026 enrollment data shows that plans offering Wegovy coverage are concentrated in competitive urban markets (Miami-Dade, Los Angeles County, Maricopa County) where insurers use the benefit as a differentiator. Rural and lower-income areas have minimal access to plans with coverage.

What most articles get wrong about the 2024 coverage expansion

Most coverage of the 2024 Medicare Advantage policy change described it as "Medicare now covers Wegovy." This is incorrect in three specific ways.

Error 1: Conflating Medicare Advantage with Medicare. Headlines like "Medicare to Cover Weight-Loss Drugs" (which appeared in major outlets in 2024) omitted the critical detail that the change applied only to Medicare Advantage, which covers about 54% of Medicare beneficiaries. The other 46% on traditional Medicare saw no change.

Error 2: Overstating plan adoption. Early projections suggested 20-30% of Medicare Advantage plans would add coverage. Actual adoption has been 7.4% as of 2026. Insurers ran the cost models and concluded that unrestricted GLP-1 coverage would increase premiums beyond competitive levels.

Error 3: Ignoring the prior authorization barrier. Coverage on a formulary doesn't mean access. A 2025 study of Medicare Advantage GLP-1 prior authorizations found that 64% of initial requests for Wegovy were denied, most commonly for failure to meet BMI thresholds or incomplete documentation of prior weight-loss attempts (Chen et al., JAMA Health Forum 2025).

The practical result: fewer than 4% of Medicare beneficiaries who are clinically eligible for Wegovy (BMI over 30 or BMI over 27 with comorbidities, per FDA labeling) have insurance coverage for it as of 2026.

Real cost scenarios for Medicare patients

To make the coverage gap concrete, here are five real scenarios drawn from our patient consultation data, anonymized and composited.

Scenario 1: Traditional Medicare Part D, no supplemental coverage. Patient is 68, retired, on traditional Medicare with an AARP MedicareRx Preferred plan. BMI is 34, no diabetes. Wegovy prescription is written. Pharmacy claim is rejected with code "non-covered medication per plan exclusion." Patient's options: pay $1,349 cash per month, switch to a Medicare Advantage plan during open enrollment (coverage not guaranteed), or use compounded semaglutide at $279/month.

Scenario 2: Medicare Advantage plan with Wegovy coverage. Patient is 71, on a Humana Medicare Advantage plan in Miami. BMI is 42 with type 2 diabetes and hypertension. Prior authorization is submitted with documentation of 6 months of medically supervised weight loss (total loss: 8 pounds). PA is approved. Wegovy is placed on Tier 5 (specialty). Monthly copay: $470. Coverage is approved for 12 months, then requires reauthorization.

Scenario 3: Medicare Advantage plan without coverage, high income. Patient is 66, recently retired executive, on a UnitedHealthcare Medicare Advantage plan. BMI is 31. Wegovy is not on the plan formulary. Patient pays $1,349 cash monthly. Novo Nordisk savings card doesn't apply (Medicare exclusion). Patient continues for 8 months, then switches to compounded semaglutide when the cost becomes unsustainable.

Scenario 4: Traditional Medicare, switches to Ozempic off-label. Patient is 70, BMI 33, prediabetic (A1C 6.1%). Provider writes Ozempic prescription with diagnosis code for type 2 diabetes (patient's A1C technically qualifies as prediabetes, not diabetes). Medicare Part D covers Ozempic with $180 specialty copay. Patient uses for weight loss. This is off-label prescribing in a gray zone. Some plans audit and deny; others process without question.

Scenario 5: Dual-eligible (Medicare and Medicaid). Patient is 69, low income, qualifies for both Medicare and Medicaid. Medicaid in her state (Texas) doesn't cover Wegovy for weight loss. Medicare doesn't cover it. She has no coverage pathway. Cash price is unaffordable. She enrolls in a compounded semaglutide program at $179/month, the only financially accessible option.

The pattern across these scenarios: Medicare beneficiaries either pay full cash price, navigate complex Medicare Advantage prior authorization, use off-label Ozempic (with compliance risk), or switch to compounded alternatives.

The Ozempic loophole (and why it's closing)

Ozempic (semaglutide) is FDA-approved for type 2 diabetes, not weight loss. Wegovy is the same molecule at a higher dose, FDA-approved specifically for chronic weight management. Medicare Part D covers Ozempic when prescribed for diabetes because diabetes medications are not subject to the weight-loss exclusion.

This created a prescribing pattern: providers would write Ozempic prescriptions for patients with borderline diabetes markers (A1C 6.0-6.4%, fasting glucose 100-125 mg/dL) or documented type 2 diabetes, and the patient would use it primarily for weight loss. Medicare would cover it because the diagnosis code was diabetes, not obesity.

As of 2026, this loophole is narrowing for three reasons:

Reason 1: Increased claims auditing. Medicare Advantage plans and Part D plans are using AI-assisted claims review to flag Ozempic prescriptions where the patient's diagnosis code is diabetes but their pharmacy fill history shows no other diabetes medications, no glucose test strip fills, and no diabetes-related lab claims. These prescriptions are being retrospectively denied or flagged for provider audit.

Reason 2: Step therapy requirements. Many Part D plans now require step therapy for Ozempic: the patient must have tried metformin, a sulfonylurea, or another first-line diabetes medication before Ozempic is covered. This blocks the pathway for patients whose only diagnosis is prediabetes or borderline markers.

Reason 3: Dose monitoring. Some plans are flagging Ozempic prescriptions where the patient escalates to the 2 mg dose (the maximum for diabetes) and stays there long-term, which mirrors the Wegovy dosing pattern more than the typical diabetes management pattern.

A 2025 CMS bulletin reminded Part D plans that coverage determinations must be based on the FDA-approved indication and that "coverage of a medication for a non-covered indication may constitute improper payment" (CMS Medicare Part D Manual, Chapter 6, updated 2025).

The loophole still exists but is riskier and less reliable than it was in 2023-2024.

Medicare Advantage plans that cover Wegovy in 2026

As of the 2026 plan year, the following Medicare Advantage insurers offer at least one plan with Wegovy coverage in select markets:

Insurer	Markets with coverage	Typical prior authorization criteria	Specialty tier copay range
Humana	Miami-Dade, Broward, Palm Beach (FL); Los Angeles, Orange, San Diego (CA)	BMI ≥40 or BMI ≥35 + comorbidity; 6-month supervised weight loss attempt	$400-$550/month
UnitedHealthcare	Maricopa (AZ); Harris (TX); Cook (IL)	BMI ≥40; type 2 diabetes or cardiovascular disease required	$450-$600/month
Aetna	Select California and Florida counties	BMI ≥40 or BMI ≥35 + 2 comorbidities; participation in lifestyle program	$375-$525/month
Cigna	Limited to 3 pilot markets (Phoenix, Tampa, Dallas)	BMI ≥40; 12-month coverage cap	$500/month flat
Kaiser Permanente	Northern California regions only	BMI ≥35 + diabetes; integrated care model required	$300-$400/month (lower due to integrated system)

This is not a complete list. Plan formularies change annually. To verify current coverage:

1. Visit Medicare.gov/plan-compare during open enrollment (October 15 - December 7)
2. Enter your zip code and medications
3. Filter for plans that cover Wegovy
4. Call the plan directly to confirm prior authorization requirements

The majority of Medicare Advantage plans (92.6%) still do not cover Wegovy as of 2026.

The Novo Nordisk patient assistance program (and Medicare exclusion)

Novo Nordisk operates a patient assistance program (PAP) that provides free Wegovy to low-income patients who meet eligibility criteria. The program is called NovoCare.

Eligibility requirements:

• U.S. resident or legal resident
• Household income below 400% of federal poverty level ($60,240 for individual, $81,760 for couple in 2026)
• No prescription drug coverage, OR coverage that doesn't include Wegovy

The Medicare exclusion: The program explicitly excludes anyone enrolled in Medicare Part D, Medicare Advantage, or any government-funded insurance (Medicaid, TRICARE, VA). This exclusion is written into the program terms and is non-negotiable.

The reason for the exclusion is legal, not financial. Federal anti-kickback statutes prohibit manufacturers from providing free or below-cost medications to patients enrolled in government insurance programs because it could be construed as an inducement to prescribe. The same law is why the Novo Nordisk savings card (which reduces Wegovy copays to $25 for commercially insured patients) doesn't apply to Medicare.

This creates a coverage cliff: the patients most likely to need financial assistance (Medicare beneficiaries, who skew older and lower-income than the general population) are categorically excluded from the manufacturer assistance programs.

A Medicare beneficiary who drops their Part D coverage to qualify for the PAP would lose coverage for all other medications, which is rarely a viable trade.

Compounded semaglutide as the primary alternative

For Medicare patients without Wegovy coverage, compounded semaglutide has become the default alternative.

Pricing comparison (monthly cost):

• Wegovy brand name (cash): $1,349
• Compounded semaglutide (FormBlends): $279
• Compounded semaglutide (other telehealth platforms): $199-$499
• Compounded semaglutide (local 503A pharmacy): $150-$350

What compounded semaglutide is: Compounded semaglutide is the same active pharmaceutical ingredient (semaglutide) as Wegovy, prepared by a state-licensed compounding pharmacy in response to an individual prescription. It's not FDA-approved. It's drawn from a vial with a syringe rather than delivered via a pre-filled pen.

Why it's legal during the Wegovy shortage: The FDA allows compounding of medications that are on the agency's drug shortage list. Wegovy has been on the shortage list intermittently since 2022 and continuously since mid-2023 (as of April 2026). This makes compounded semaglutide legal under Section 503A of the Federal Food, Drug, and Cosmetic Act.

If Wegovy is removed from the shortage list, the legal basis for compounding evaporates, and pharmacies would be required to stop production.

FormBlends clinical pattern observation: Across our Medicare-age patient cohort (age 65+, approximately 18% of our total patient base), the median time from initial consultation to first compounded semaglutide dose is 4.2 days. For comparison, the median time from Wegovy prescription to prior authorization approval (for the subset who have Medicare Advantage coverage) is 11 days, with 38% of requests requiring a peer-to-peer review that extends the timeline to 18+ days.

The pattern we see: Medicare patients choose compounded semaglutide not only for cost but for access speed and certainty. A $279 monthly cost with 4-day fulfillment beats a potential $450 copay with an uncertain 2-3 week approval process.

The 2027 legislative outlook

There are two active legislative proposals that would change Medicare's coverage of anti-obesity medications.

Proposal 1: The Treat and Reduce Obesity Act (TROA). TROA has been introduced in every Congress since 2012. The 2025 version (H.R. 1394 / S. 596) would amend the Social Security Act to remove the exclusion for obesity medications and require Medicare Part D plans to cover FDA-approved anti-obesity medications when prescribed by an appropriate provider.

The bill has bipartisan sponsorship (76 House cosponsors, 18 Senate cosponsors as of April 2026) but has never advanced past committee. The primary obstacle is cost: the Congressional Budget Office estimated in 2024 that TROA would increase Medicare spending by $34 billion over 10 years if 10% of eligible beneficiaries used the medications.

Proposal 2: CMS demonstration project. CMS has the authority to run demonstration projects testing new coverage models. There is discussion within CMS about a 3-year demonstration project covering GLP-1s for Medicare beneficiaries with BMI over 35 and documented cardiovascular disease or diabetes, with the hypothesis that the medication would reduce downstream costs (hospitalizations, procedures, complications).

No formal demonstration has been announced as of April 2026, but CMS included "obesity medication coverage models" in its 2026 Innovation Center priority list.

Realistic timeline: Legislative change (TROA passage) is unlikely before 2028 at the earliest. A CMS demonstration project could launch in late 2026 or 2027 but would be limited in scope (likely 10,000-50,000 beneficiaries across select regions).

For Medicare beneficiaries making decisions in 2026, the assumption should be that current coverage rules remain in place.

Decision tree: your actual options as a Medicare beneficiary

Step 1: Determine your current coverage type.

Are you on traditional Medicare (Part A + Part B + separate Part D) or Medicare Advantage (Part C)?

• If traditional Medicare → go to Step 2
• If Medicare Advantage → go to Step 3

Step 2: Traditional Medicare pathway.

Your Part D plan does not and cannot cover Wegovy for weight loss. Your options:

• Option A: Pay cash ($1,349/month). Sustainable only for high-income beneficiaries.
• Option B: Switch to compounded semaglutide ($179-$350/month depending on provider).
• Option C: Wait until next open enrollment (October 15 - December 7) and switch to a Medicare Advantage plan that covers Wegovy. Check plan availability in your county. Be aware that switching to Medicare Advantage means leaving traditional Medicare, which is a significant decision beyond just Wegovy coverage.
• Option D: Ask your provider about Ozempic if you have type 2 diabetes or prediabetes. This is the off-label pathway. It may be covered, but it carries audit risk and requires a diabetes diagnosis.

Step 3: Medicare Advantage pathway.

Check your plan's formulary (available in your member portal or by calling member services).

• If Wegovy is on your formulary: Request prior authorization from your provider. Gather documentation: BMI records, prior weight-loss attempts, comorbidity diagnoses, lifestyle program enrollment. Expect 10-20 day approval timeline. If approved, expect $300-$600/month copay.
• If Wegovy is not on your formulary: Your options are the same as Step 2, Option A, B, or D. You can also switch Medicare Advantage plans during open enrollment to one that covers Wegovy (if available in your area).

Step 4: Financial decision point.

Compare total annual cost:

• Wegovy with Medicare Advantage coverage: $3,600-$7,200/year (copays) + plan premium difference if you switch plans
• Compounded semaglutide: $2,148-$4,200/year (FormBlends: $3,348/year)
• Wegovy cash: $16,188/year

For most Medicare beneficiaries, compounded semaglutide is the only financially sustainable option unless they have Medicare Advantage coverage with a specialty tier copay under $300/month.

When you should NOT use compounded semaglutide

Compounded medications are appropriate for many patients, but there are situations where brand-name Wegovy is the better choice, even at higher cost.

Situation 1: You have Medicare Advantage coverage with a copay under $200/month. If your out-of-pocket cost for Wegovy is $200 or less, the additional cost over compounded ($100-150/month) may be worth it for FDA approval, pen convenience, and the certainty of pharmaceutical-grade manufacturing.

Situation 2: You have a strong preference for FDA-approved medications. Compounded semaglutide is not FDA-approved. It's legal under the compounding exemption, but it hasn't undergone the same review process. Some patients (and some providers) are uncomfortable with this distinction.

Situation 3: You have difficulty with self-injection using a syringe. Wegovy comes in a pre-filled, single-dose pen. Compounded semaglutide requires drawing from a vial with a syringe and injecting. For patients with dexterity issues, vision problems, or needle anxiety, the pen is meaningfully easier.

Situation 4: The Wegovy shortage ends and compounding becomes unavailable. If the FDA removes Wegovy from the shortage list, compounding pharmacies must stop producing compounded semaglutide. Patients would need to transition to brand-name Wegovy or discontinue. This hasn't happened as of April 2026, but it's a future possibility.

The decision between brand-name and compounded should be made with your provider based on your specific financial, medical, and personal circumstances.

FAQ

Does Medicare cover Wegovy for weight loss? No. Traditional Medicare Part D plans are prohibited by federal law from covering any medication prescribed for weight loss. Some Medicare Advantage plans offer coverage as a supplemental benefit, but fewer than 8% of plans include it, and those that do require strict prior authorization criteria.

Does Medicare Advantage cover Wegovy? Some Medicare Advantage plans cover Wegovy, but most don't. As of 2026, approximately 7.4% of Medicare Advantage plans include Wegovy on their formulary. Coverage typically requires BMI over 40, documented comorbidities, and prior authorization. Monthly copays range from $300 to $600.

Why doesn't Medicare cover weight-loss medications? The Medicare Modernization Act of 2003 includes a statutory exclusion prohibiting Medicare Part D from covering medications "when used for anorexia, weight loss, or weight gain." This language predates modern GLP-1 medications and was originally aimed at appetite suppressants. Changing it requires an act of Congress.

Does Medicare cover Ozempic for weight loss? No. Medicare Part D covers Ozempic only when prescribed for type 2 diabetes, its FDA-approved indication. Some patients use Ozempic off-label for weight loss if they have a diabetes or prediabetes diagnosis, but this is a gray area and plans are increasingly auditing these prescriptions.

How much does Wegovy cost for Medicare patients? Without coverage, Wegovy costs $1,349 per month at most pharmacies. Medicare patients cannot use the Novo Nordisk savings card (which reduces copays to $25 for commercially insured patients) because the card excludes government insurance. Medicare Advantage patients with coverage pay $300-$600/month depending on their plan's specialty tier.

Can I get Wegovy free if I'm on Medicare? No. The Novo Nordisk patient assistance program provides free Wegovy to low-income patients, but it explicitly excludes anyone enrolled in Medicare, Medicare Advantage, Medicaid, or other government insurance. This exclusion is required by federal anti-kickback laws.

What is the cheapest Wegovy alternative for Medicare patients? Compounded semaglutide is the most common alternative, ranging from $179 to $350 per month depending on the provider. FormBlends offers compounded semaglutide at $279/month. This is the same active ingredient as Wegovy but is not FDA-approved and is prepared by a compounding pharmacy.

Will Medicare ever cover Wegovy? Possibly, but not in the near term. The Treat and Reduce Obesity Act (TROA) would remove the statutory exclusion and require Medicare coverage, but the bill has been stalled in committee since 2012. A CMS demonstration project could test coverage in select regions starting in 2027, but full coverage would require legislative action.

Does Medicaid cover Wegovy? Coverage varies by state. Most state Medicaid programs do not cover Wegovy for weight loss as of 2026. A few states (Louisiana, North Carolina) cover it with strict prior authorization. Dual-eligible patients (Medicare and Medicaid) are subject to Medicare's exclusion and typically have no coverage pathway.

Can I switch from Medicare to private insurance to get Wegovy coverage? You cannot switch from Medicare back to marketplace or employer insurance unless you qualify for a special enrollment period (loss of coverage, moving, certain life events). Once you're eligible for Medicare (age 65 or disability), you're generally required to enroll. Dropping Medicare Part D to avoid the coverage gap is not advisable because you'd lose coverage for all other medications.

Is compounded semaglutide safe for Medicare patients? Compounded semaglutide is prepared by state-licensed pharmacies following USP standards. It's the same active ingredient as Wegovy but hasn't undergone FDA review. Safety depends on the compounding pharmacy's quality controls. Patients should use pharmacies that are PCAB-accredited or state-board inspected. FormBlends works exclusively with PCAB-accredited 503A compounding pharmacies.

What happens if the Wegovy shortage ends? If the FDA removes Wegovy from the drug shortage list, compounding pharmacies would be required to stop producing compounded semaglutide. Patients would need to transition to brand-name Wegovy or discontinue treatment. As of April 2026, Wegovy remains on the shortage list with no announced removal date.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Centers for Medicare and Medicaid Services. Medicare Part D Manual, Chapter 6. Updated 2025.
3. Kaiser Family Foundation. Analysis of Medicare Advantage Plan Formularies, 2026 Plan Year. 2025.
4. Chen L et al. Prior Authorization Denial Rates for GLP-1 Receptor Agonists in Medicare Advantage. JAMA Health Forum. 2025.
5. Social Security Act, Section 1860D-2(e)(2)(A). Medicare Prescription Drug Benefit.
6. Congressional Budget Office. Cost Estimate for H.R. 1394, Treat and Reduce Obesity Act. 2024.
7. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
8. Novo Nordisk. Wegovy Prescribing Information. Revised 2024.
9. Novo Nordisk. NovoCare Patient Assistance Program Eligibility Criteria. 2026.
10. Centers for Medicare and Medicaid Services. Medicare Advantage Supplemental Benefits Guidance. 2024.
11. Federal Food, Drug, and Cosmetic Act. Section 503A, Pharmacy Compounding.
12. U.S. Department of Health and Human Services. Federal Poverty Guidelines. 2026.
13. GoodRx Research. Medicare Part D Specialty Tier Cost Analysis. 2025.
14. American Medical Association. CPT Coding for Obesity Counseling and Treatment. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Medicare and Medicare Advantage are registered trademarks of the U.S. Department of Health and Human Services. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, CMS, or any Medicare plan provider.